MedTrace Logo

Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

NCT04168099 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-11-19

No results posted yet for this study

Summary

oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis

Conditions

  • Spontaneous Bacterial Peritonitis

Interventions

DRUG

Cefotaxime

Cefotaxime IV

DRUG

Gemifloxacin

Gemifloxacin oral

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Hala Shaaban El Gendy, Msc · Tanta University - Faculty of Medicine

  • Osama El Sayed Negm, Prof. · Tropical Medicine Dept.-Tanta University - Faculty of Medicine

  • Sherief Abd-Elsalam, Ass. Prof. · Tropical Medicine Dept.-Tanta University - Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2028-12-01
Completion
2028-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04168099 on ClinicalTrials.gov